Circular Genomics Raises $8.3 Million for Debut of Circular RNA Assay in Precision Psychiatry
Summary
"We plan to launch our first test in 2024, which will predict response to SSRI antidepressants, addressing the issue of high therapy failure rates, and low clinical outcomes. Furthermore, the launch of this first assay paves the way for a set of tests covering the complete patient care continuum in major depression, and using the same circular RNA platform, in other neurological diseases too." Circular Genomics is at the forefront of introducing precision medicine into mental health care, promising a future where treatments are tailored to individual patients, improving outcomes, and providing deeper understanding of these complex conditions. Leveraging exclusive licenses and pioneering technologies in circular RNA, we are reshaping the standard of care for major depressive disorder and other neurological diseases. Mountain Group Partners is a Nashville-based venture capital firm that invests in early-stage companies, predominantly in the life science and disruptive technology sectors.